Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

fludarabine 52Cyclophosphamide 50venetoclax 47Azacitidine 44fludarabine phosphate 41Whole-Body Irradiation 33Specimen Handling 31Mycophenolic Acid 30Tacrolimus 28Melphalan 28Busulfan 27Cytarabine 25Stem Cell Transplantation 23Decitabine 23Biopsy 22Granulocyte Colony-Stimulating Factor 19Sirolimus 16Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Thiotepa 15decitabine and cedazuridine drug combination 14Injections 13Cyclosporine 13ruxolitinib 9Methotrexate 9Mesna 9Hematopoietic Stem Cell Transplantation 9X-Rays 8Idarubicin 8Daunorubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × midostaurin × 1 year × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡